Distribution of human papillomavirus genotypes in Paraguayan women according to the severity of the cervical lesion

Journal of Medical Virology

Volumn 83, Issue 8, 2011, Pages 1351-1357

  Mendoza, L P ^a   Arbiza, J ^b   Paez, M ^a   Kasamatsu, E ^a   Castro, A ^a   Gimenez G ^a   Basiletti, J ^c   Gonzalez, J ^c   Mongelos P ^a   Picconi, M A ^c  

^a Health Sciences Research Institute (IICS)   (Paraguay)

^b UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^c INSTITUTO NACIONAL DE ENFERMEDADES INFECCIOSAS   (Argentina)

Author keywords

Cervical cancer; Cross sectional study; HPV genotypes; Pre cancer

Indexed keywords

PRIMER DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CROSS-SECTIONAL STUDY; DECISION MAKING; DISEASE SEVERITY; FEMALE; GENOTYPE; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; HYBRIDIZATION; INCIDENCE; MAJOR CLINICAL STUDY; PARAGUAY; POLYMERASE CHAIN REACTION; PREVALENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SQUAMOUS EPITHELIUM; TISSUE INJURY; UTERINE CERVIX CANCER; UTERINE CERVIX DISEASE; VACCINATION; WART VIRUS;

ADOLESCENT; ADULT; AGED; CARCINOMA; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PARAGUAY; PREVALENCE; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 79959254926     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22112     Document Type: Article

References (31)

1. Bernard HU, Chan SY, Manos MM, Ong CK, Villa LL, Delius H, Peyton CL, Bauer HM, Wheeler CM. 1994. Identification and assessment of known and novel human papillomavirus by polymerase chain reaction amplification, restriction fragment lengh polymorphisms, nucleotide sequence and phylogenetic algorithms. J Infect Dis 170: 1077-1085.
2. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Muñoz N. 2008. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 26: K1-K16.
3. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V. WHO International Agency for Research on Cancer Monograph Working Group. 2009. A review of human carcinogens-Part B: Biological agents. Lancet Oncol 10: 321-322.
4. Brotherton JM, Kaldor JM, Garland SM. 2010. Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: Towards a national HPV surveillance strategy. Sex Health 7: 310-319.
5. Castle PE, Solomon D, Schiffman M, Wheeler CM. for the ALTS Group. 2005. Human papillomavirus type 16 infections and two-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 97: 1066-1071.
6. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. 2005. Human papillomavirus genotype distribution in low-grade cervical lesions: Comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14: 1157-1164.
7. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menéndez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, Andújar M, Castellsagué X, Sánchez GI, Nowakowski AM, Bornstein J, Muñoz N, Bosch FX. Retrospective International Survey and HPV Time Trends Study Group. 2010. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol 11: 1048-1056.
8. de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX. 2007. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: A meta-analysis. Lancet Infect Dis 7: 453-459.
9. Evans MF, Adamson CS, Schned LM, St John TL, Leiman G, Ashikaga T, Cooper K. 2010. HPV is detectable in virtually all abnormal cervical cytology samples after reinvestigation of HPV negatives with multiple alternative PCR tests. Diagn Mol Pathol 19: 144-150.
10. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
11. Harper DM. 2009. Currently approved prophylactic HPV vaccines. Expert Rev Vaccines 8: 1663-1679.
12. Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, Morales J, Alfaro M, Sherman ME, Wacholder S, Chen S, Rodriguez AC, Burk RD. 2005. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 191: 1796-1807.
13. Hulley SB, Cummings SR, Browner WS, Grady DG, Newman TB. 2007. Designing clinical research 3rd edition. Philadelphia, PA: Wolters Kluwer; Lippincott Williams and Wilkins. p. 97.
14. Kasamatsu E, Ascurra M, Hullin C, Nakajima T, Shozawa T. 1996. Detection and typing of human papillomavirus DNA in invasive squamous cell carcinoma of the cervix by polymerase chain reaction and its correlation with histopathological findings. Anales de la Facultad de Ciencias Médicas 29: 317-333.
15. Kjaer SK, Breugelmans G, Munk C, Junge J, Watson M, Iftner T. 2008. Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer 123: 1864-1870.
16. Kjær SK, Frederiksen K, Munk C, Iftner T. 2010. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: Role of persistence. J Natl Cancer Inst 102: 1478-1488.
17. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. 2011. Human papillomavirus type distribution in 30, 848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 128: 927-935.
18. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM. 1989. The use of polymerase chain reaction amplification of DNA with a thermostable DNA polymerase. Cancer Cell 7: 209-214.
19. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527.
20. Quint W, Molijn A, Colau B, van der Sandt M, Jenkins D. 2009. One HPV virus, one lesion as determined by lcm/pcr technology. Int Papillomavirus Conference, Malmö, Sweeden. Abstract O-06.04, p 06.3.
21. Rodríguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME, Solomon D, Guillén D, Alfaro M, Morales J, Hutchinson M, Katki H, Cheung L, Wacholder S, Burk RD. 2010. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: Critical role of duration of infection. J Natl Cancer Inst 102: 315-324.
22. Rolón PA, Smith JS, Muñoz N, Klug SJ, Herrero R, Bosch X, Llamosas F, Meijer CJ, Walboomers JM. 2000. Human papillomavirus infection and invasive cervical cancer in Paraguay. Int J Cancer 85: 486-491.
23. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA. 1988. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239: 487-491.
24. Sato Y, Sugie R, Tsuchiya B, Kameya T, Natori M, Mukai K. 2001. Comparison of the DNA extraction methods for polymerase chain reaction amplification from formalin-fixed and paraffin-embedded tissues. Diagn Mol Pathol 10: 265-271.
25. Schmitt M, Dondog B, Waterboer T, Pawlita M, Tommasino M, Gheit T. 2010. Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J Clin Microbiol 48: 143-149.
26. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. 2007. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer 121: 621-632.
27. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T, Jr, Young N. Forum Group Members; Bethesda 2001 Workshop. 2002. The 2001 Bethesda System. Terminology for reporting results of cervical cytology. JAMA 267: 2114-2119.
28. Spinillo A, Dal Bello B, Gardella B, Roccio M, Dacco' MD, Silini EM. 2009. Multiple human papillomavirus infection and high grade cervical intraepithelial neoplasia among women with cytological diagnosis of atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions. Gynecol Oncol 113: 115-119.
29. Trottier H, Mahmud S, Costa MC, Sobrinho JP, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL. 2006. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 15: 1274-1280.
30. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. 2002. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 40: 779-787.
31. WHO. HPV Position paper.